Auris Medical Provides Business Update and Reports First Half 2020 Financial Results

  • Advancing Phase 2 trial with AM-125 in acute vertigo based on positive interim data

  • Positive outcome from AM-201 trial in prevention of antipsychotic-induced weight gain

  • Addition of new intranasal program with development of drug-free spray for protection against airborne pathogens and allergens

  • Review of strategic options initiated

Hamilton, Bermuda, September 17, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today provided a business update and announced financial results for the first half of the 2020 financial year ended June 30, 2020.

“Over the past few months we reached major milestones with our intranasal betahistine program, reporting positive safety and tolerability data as well as significant efficacy signals in two clinical trials,” stated Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “The demonstration of a dose-dependent improvement in various vertigo measures

Read More